People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| GT Biopharma, Inc. | — | Biotechnology | Series B | $53.5M | $98.2M | 2025 |
| Qualigen Therapeutics, Inc. | — | Biotechnology | Series A | $27.9M | $14.1M | 2009 |
| Myosin Therapeutics Inc. | — | Pharmaceuticals | Seed | $3.0M | $32.4M | 2022 |
Andrew Ritter at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Andrew Ritter on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Noah Doyle | 1 | 19 |
| Paul V. Maier | 1 | 6 |
| Charles Casamento | 1 | 5 |
| Robert Finizio | 1 | 4 |
| Matthew W. Foehr | 1 | 4 |
| Jackson Streeter | 1 | 4 |
| Braeden Lichti | 1 | 3 |
| Campbell Becher | 1 | 3 |
| Graydon Bensler | 1 | 3 |
| Michael Breen | 1 | 3 |
| Bruce Wendel | 1 | 2 |
| THOMAS ADAMEK | 1 | 2 |
| David Saloff | 1 | 2 |
| Anthony Cataldo | 1 | 2 |
| Dave Adams | 1 | 2 |
| Ira Ritter | 1 | 2 |
| Kevin Richardson II | 1 | 2 |
| Steven Weldon | 1 | 2 |
| Ira E. Ritter | 1 | 2 |
| STEVEN J. MARKOWITZ | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.